Biopharmaceutical company Oneness Biotech Co Ltd (TW:4743) and Microbio (Shanghai) Co Ltd, a developer of innovative small nucleic acid drugs, announced on Friday that their jointly developed broad-spectrum antiviral siRNA drug SNS812 has been selected for oral presentation at the 2025 American Thoracic Society (ATS) International Conference.

SNS812 is the world's first fully modified siRNA drug, clinically validated and administered through aerosol inhalation, providing broad-spectrum inhibitory activity to combat the SARS-CoV-2 virus.

Results from a Phase II clinical trial show that SNS812 significantly reduces viral load, accelerates the resolution of symptoms such as shortness of breath, and smell and taste loss, and has excellent safety and tolerability.

The presentation will be delivered in a Mini Symposium, the highest-tier session format at the ATS conference.